MBIO

Mustang Bio Inc

0.3795

Oct 21 • 10:17 AM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: TCRT ESLA ATRA CRBU ACET CLLS SNTI GTBP IPSC NKTX

Index	-
Market Cap	2.88M
Enterprise Value	-12.27M
Income	-3.03M
Sales	0.00M
Book/sh	1.00
Cash/sh	2.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Aug 22, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.38
P/C	0.19
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.97
Current Ratio	1.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.45
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	91.14% 78.52%
Sales past 3/5Y	- -
EPS Y/Y TTM	85.52%
Sales Y/Y TTM	-
EPS Q/Q	15.99%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	-150.00% -

Insider Own	14.98%
Insider Trans	0.00%
Inst Own	7.11%
Inst Trans	0.41%
ROA	-21.17%
ROE	-58.12%
ROIC	-40.20%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.51%
SMA50	-24.32%
SMA200	-46.77%
Trades

Shs Outstand	6.73M
Shs Float	6.44M
Short Float	0.82%
Short Ratio	1.66
Short Interest	0.05M
52W High	1.57 -75.83%
52W Low	0.37 2.54%
Volatility	8.57% 6.73%
ATR (14)	0.03
RSI (14)	29.66
Beta	2.20
Rel Volume	1.08
Avg Volume	31.66K
Volume	6,631

Perf Week	2.54%
Perf Month	-28.53%
Perf Quarter	-33.43%
Perf Half Y	-50.39%
Perf YTD	-61.31%
Perf Year	-75.52%
Perf 3Y	-99.55%
Perf 5Y	-99.98%
Perf 10Y	-
Recom	1.00
Target Price	500.00
Prev Close	0.38
Price	0.38
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-21	Initiated	BTIG Research	Buy	$11
Oct-02-20	Initiated	B. Riley FBR	Buy	$9
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight	$7
Aug-13-19	Initiated	H.C. Wainwright	Buy	$7
Jun-21-19	Initiated	Cantor Fitzgerald	Overweight	$7
Dec-21-17	Initiated	Oppenheimer	Outperform	$18

Jul-08-25 10:38AM	MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy (Zacks) -20.36%
Jul-07-25 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma (GlobeNewswire) +180.67%
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire) +5.56% -9.36%
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire) -27.01%
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
08:00AM	Loading…
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire) +5.40%
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire) -35.77%
Nov-12-24 08:30AM	Mustang Bio Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Nov-08-24 06:36AM	Mustang Bios MB-108 receives FDA orphan drug status for glioma treatment (Pharmaceutical Technology)
Nov-07-24 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma (GlobeNewswire)
Oct-26-24 05:20PM	Mustang Bio Secures $4M through Strategic Warrant Agreement (TipRanks)
Oct-24-24 02:10PM	Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds (GlobeNewswire)
Jun-28-24 08:00AM	Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Jun-21-24 04:01PM	Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
05:26PM	Loading…
Jun-20-24 05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire) -34.07%
08:00AM	Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 10:22AM	Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study (Zacks) +13.35%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:30AM	Citi raises its S&P 500 target, Boeing CEO testifies: Yahoo Finance (Yahoo Finance Video)
Jun-17-24 01:28PM	ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation (InvestorPlace) +476.92%
01:03PM	AAN Stock Alert: The Aaron's Company Pops 33% on Take-Private Deal (InvestorPlace)
12:07PM	Why Is Mustang Bio (MBIO) Stock Up 347% Today? (InvestorPlace)
08:30AM	Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy (GlobeNewswire)
May-22-24 08:04AM	Why Is Mustang Bio (MBIO) Stock Up 58% Today? (InvestorPlace) -22.58%
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-16-24 10:53AM	MBIO Stock Earnings: Mustang Bio Beats EPS for Q1 2024 (InvestorPlace) +8.54%
May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire) +12.65% +8.46%
Apr-30-24 06:03AM	Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants (MT Newswires)
08:00PM	Loading…
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire) -25.02%
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.64%
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.20% -8.62%
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) +5.30%
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -7.14%
Nov-14-23 04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-02-23 09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -10.19%
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Sep-07-23 08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire)
Aug-14-23 04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -11.04% -5.71%
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire) +8.56%
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.78%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.76% +9.44%
Jun-13-23 01:49PM	Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data (Zacks) -6.29%
Jun-12-23 09:55AM	Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet (Zacks) +9.16%
08:00AM	Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire)
May-26-23 09:55AM	Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade (Zacks)
May-18-23 08:03AM	Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire)
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.65%
May-12-23 04:05PM	Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-11-23 04:03PM	Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy (GlobeNewswire)
Apr-03-23 12:15PM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire) -11.32%
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.30%
Mar-29-23 04:15PM	Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-23 08:30AM	Mustang Bio to Participate in Cantors The Future of Oncology Virtual Symposium (GlobeNewswire)
Jan-17-23 08:15AM	Mustang Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +9.19%
Dec-19-22 08:30AM	Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones (GlobeNewswire) -10.09%
Nov-14-22 04:05PM	Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Oct-27-22 08:00AM	Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia (GlobeNewswire) +5.17%
Oct-06-22 08:30AM	Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire)
Sep-08-22 08:00AM	Mustang Bio to Participate in Upcoming September 2022 Investor Conferences (GlobeNewswire)
Sep-02-22 09:55AM	Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing (Zacks)
Aug-11-22 04:05PM	Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-27-22 08:00AM	Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency (GlobeNewswire)
Jul-17-22 08:21AM	Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year (Simply Wall St.)
Jun-22-22 08:00AM	Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia (GlobeNewswire) +12.57%
Jun-13-22 08:00AM	Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy (GlobeNewswire)
May-19-22 03:23PM	Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency (Benzinga)
08:45AM	Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 (GlobeNewswire)
May-12-22 04:05PM	Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.56%
10:38AM	Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress (GlobeNewswire)
May-03-22 08:00AM	Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting (GlobeNewswire) -5.35%
Apr-25-22 08:00AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire)
Apr-21-22 08:30AM	Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations (GlobeNewswire) -5.16%
Apr-13-22 10:00AM	Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13R2targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma (GlobeNewswire)
Apr-04-22 08:00AM	Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities (GlobeNewswire) +8.65%
Apr-01-22 08:30AM	Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 (GlobeNewswire)
Mar-23-22 04:05PM	Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.71% +22.58%
Mar-10-22 08:30AM	Mustang Bio to Participate in Three March 2022 Investor Conferences (GlobeNewswire) -6.41%
Mar-09-22 08:00AM	Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Childrens Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) +14.18%
Mar-08-22 09:00AM	Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital (GlobeNewswire)
Feb-15-22 07:30AM	Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (GlobeNewswire) +6.93%
Feb-08-22 08:30AM	Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards (GlobeNewswire)
Feb-07-22 09:11AM	One Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their stake by 25% in the previous year (Simply Wall St.)
Jan-25-22 07:10AM	FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder (Benzinga) -6.15%
Jan-24-22 05:00PM	Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (XSCID) in Previously Transplanted Patients (GlobeNewswire)
Jan-07-22 02:05PM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-05-22 08:30AM	Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences (GlobeNewswire) -5.26%
Dec-16-21 08:30AM	Mustang Bio Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-13-21 09:00AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire) -11.59%
Dec-09-21 08:30AM	Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia (GlobeNewswire)
Dec-06-21 07:30AM	Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation (Simply Wall St.)
Nov-12-21 08:05AM	Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herskowitz Neil	Director	Dec 30 '25	Sale	0.96	247	238	145	Dec 30 04:17 PM
Chill Adam J.	Director	Dec 30 '25	Sale	0.95	4	4	375	Dec 30 04:16 PM
Jin David	Director	Dec 30 '25	Buy	0.96	247	238	286	Dec 30 04:15 PM

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

J.D.Mr. Michael S. Weiss Esq.

PresidentDr. Manuel Litchman M.D.

Controller & Interim Chief Accounting OfficerMr. Peter Carney

Chief Quality OfficerMr. Greg Furrow M.S.

Corporate SecretaryMs. Robyn M. Hunter

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBIO

Mustang Bio Inc

Upgrade your Finviz experience